A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: a behavioral and neurochemical study
- PMID: 11478934
- DOI: 10.1016/s0006-8993(01)02680-4
A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: a behavioral and neurochemical study
Abstract
The purpose of this study was to examine the influence of chronic d-amphetamine (AMPH) treatment (2 mg/kg i.p., for 9 consecutive days) on behavioral and neurochemical responses to a subsequent exposure - 4 days after the last AMPH injection--to the elevated plus-maze (EPM), as well as to determine the involvement of a dopaminergic mechanism in that influence. Results showed that chronic AMPH treatment induced an 'anxiogenic-like' response when animals were evaluated in the EPM test. Pretreatment with either haloperidol (HAL, 1 mg/kg i.p., 20 min prior to each injection) or SCH-23390 (0.1 mg/kg i.p., 10 min prior to each injection) completely abolished the chronic AMPH-induced 'anxiogenic-like' effect displayed in the EPM test. However, sulpiride pretreatment (60 mg/kg i.p., 10 min prior to each AMPH injection) did not modify such effect. In addition, rats treated with AMPH and subsequently exposed to the EPM, showed a decrease in the maximal GABA-stimulated chloride uptake in cortical microsacs. HAL pretreatment restored the maximal chloride uptake induced by chronic AMPH. Altogether, these results suggest that: (1) previous exposure to chronic AMPH treatment induces an increased emotional response following a conflict situation, (2) dopamine D(1) receptors are mainly involved in chronic AMPH-induced changes in the behavior displayed in EPM test, and (3) an interaction between GABAergic and dopaminergic mechanisms may be implicated in neurochemical and behavioral changes induced by chronic AMPH treatment.
Similar articles
-
Role of dopaminergic DAD1 and DAD2 receptors in the sensitization of amphetamine-suppressed schedule-induced polydipsia in rats.Chin J Physiol. 2009 Oct 31;52(5):280-8. doi: 10.4077/cjp.2009.amh035. Chin J Physiol. 2009. PMID: 20034231
-
Chemistry to cognition: Therapeutic potential of (m-CF3-PhSe)2 targeting rats' striatum dopamine proteins in amphetamine dependence.Prog Neuropsychopharmacol Biol Psychiatry. 2025 Jan 10;136:111238. doi: 10.1016/j.pnpbp.2024.111238. Epub 2024 Dec 26. Prog Neuropsychopharmacol Biol Psychiatry. 2025. PMID: 39732316
-
Amphetamine-induced effects on neuropeptide Y in the rat brain.Pharmacol Rep. 2005 May-Jun;57(3):321-9. Pharmacol Rep. 2005. PMID: 15985714
-
Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis.Brain Res. 1986 Jun;396(2):157-98. doi: 10.1016/s0006-8993(86)80193-7. Brain Res. 1986. PMID: 3527341 Review.
-
Amphetamine effects on striatal neurons: implications for models of dopamine function.Neurosci Biobehav Rev. 1998 Sep;22(5):613-22. doi: 10.1016/s0149-7634(97)00057-2. Neurosci Biobehav Rev. 1998. PMID: 9662723 Review.
Cited by
-
Persistent downregulation of hippocampal CREB mRNA parallels a Y-maze deficit in adolescent rats following semi-chronic amphetamine administration.Br J Pharmacol. 2008 May;154(2):417-28. doi: 10.1038/bjp.2008.126. Br J Pharmacol. 2008. PMID: 18475255 Free PMC article.
-
Behavioral effects of ketamine and toxic interactions with psychostimulants.BMC Neurosci. 2006 Mar 16;7:25. doi: 10.1186/1471-2202-7-25. BMC Neurosci. 2006. PMID: 16542420 Free PMC article.
-
Social behavior effects of diphenyl dimethyl bicarboxylate (DDB) in the sensory contact model.Naunyn Schmiedebergs Arch Pharmacol. 2019 Mar;392(3):313-326. doi: 10.1007/s00210-018-1580-7. Epub 2018 Nov 28. Naunyn Schmiedebergs Arch Pharmacol. 2019. PMID: 30488342
-
Locomotion changes in methamphetamine and amphetamine withdrawal: a systematic review.Front Pharmacol. 2024 Jul 17;15:1428492. doi: 10.3389/fphar.2024.1428492. eCollection 2024. Front Pharmacol. 2024. PMID: 39086393 Free PMC article.
-
Functional aspects of estrogen neuroprotection.Endocrine. 2003 Jun;21(1):33-41. doi: 10.1385/endo:21:1:33. Endocrine. 2003. PMID: 12777701 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous